Myogen To Announce 2005 Third Quarter Results On November 2, 2005

DENVER, Oct. 20 /PRNewswire-FirstCall/ -- Myogen, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that it will report 2005 third quarter results the afternoon of Wednesday, November 2, 2005.

J. William Freytag, President and CEO, and other members of Myogen's senior management will provide a company update and discuss results via webcast and conference call on Wednesday, November 2, 2005 at 4:30 pm Eastern. To access the live webcast, please log on to the company's website at and go to the Investor Relations section. Alternatively, callers may participate in the conference call by dialing 800-257-1927 (domestic) or 303-205-0066 (international). Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Wednesday, November 16, 2005. Callers can access the replay by dialing 800-405-2236 (domestic) or 303-590-3000 (international). The passcode is 11042459#.

About Myogen

Myogen currently markets one product (Perfan(R) I.V.) in Europe for the treatment of acute decompensated heart failure and has two product candidates in late-stage clinical development: ambrisentan for the treatment of patients with pulmonary arterial hypertension and darusentan for the treatment of patients with resistant hypertension. The company, in collaboration with Novartis, also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit our website at

Safe Harbor Statement

The 2005 third quarter results press release and conference call will contain forward-looking statements that involve significant risks and uncertainties, including those that can be found in the "Risk Factors" section of Myogen's Form 10-K for the year ended December 31, 2004 and in Myogen's periodic reports on Form 10-Q and Form 8-K. Myogen is providing the information contained in the release and conference call as of the date of the release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. The company cautions investors not to place undue reliance on the forward-looking statements contained in the press release or the conference call. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.

Myogen, Inc.

CONTACT: Derek K. Cole, Director, Investor Relations of Myogen, Inc.,+1-303-464-3986,

Back to news